Stockscreener 앱 받기
62.69
0.71%
0.44
시장 영업 전:
64.58
1.89
+3.01%
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investmentsWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportWeekly Trend Report & Safe Swing Trade Setups - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthSwing Trade & Technical Pattern Based Buy Signals - newser.com
Tick level data insight on Palvella Therapeutics Inc. volatilityEarnings Beat & Weekly High Potential Stock Alerts - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stockJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Published on: 2025-09-29 15:57:39 - newser.com
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsJuly 2025 Earnings & High Win Rate Trade Alerts - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Trade Analysis Report & Risk Managed Trade Strategies - newser.com
Published on: 2025-09-29 09:58:44 - newser.com
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas - MyChesCo
Published on: 2025-09-29 07:36:24 - newser.com
Equities Analysts Offer Predictions for PVLA FY2028 Earnings - Defense World
Published on: 2025-09-28 21:37:00 - newser.com
Palvella Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Budget Friendly Portfolio - earlytimes.in
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MyChesCo
What analysts say about Palvella Therapeutics Inc stockHealthcare Stock Analysis & Minimal Investment Capital - earlytimes.in
Palvella Expands QTORIN Gel Program for Rare Disease - MSN
Best data tools to analyze Palvella Therapeutics Inc. stockPortfolio Return Report & Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-09-27 05:34:37 - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Analyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan Capital - MarketBeat
Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Chardan Raises Price Target on Palvella Therapeutics to $73 From $60, Keeps Buy Rating - MarketScreener
Goldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics stock price target raised to $70 at Jones Trading - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments By Investing.com - Investing.com South Africa
Stifel Maintains 'Buy' Rating and Raises Price Target for PVLA t - GuruFocus
Stifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00 - MarketBeat
Palvella Therapeutics stock price target raised to $80 by Stifel on new skin treatment - Investing.com Canada
Palvella Therapeutics stock price target raised to $90 from $85 at Oppenheimer - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments - Investing.com Canada
2.36%
1.10%
자본화:
|
볼륨(24시간):